Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: A phase I study

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1317-1321

  Stathopoulos, G P ^a   Rigatos, S K ^a   Stathopoulos, J ^a  

^a Errikos Dunant Hospital   (Greece)

Author keywords

Dose escalation; Lipoplatin; Liposomal cisplatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN DERIVATIVE; CREATININE; GLUCOSE; HEMOGLOBIN; LIPOPLATIN; PACLITAXEL; UNCLASSIFIED DRUG; UREA; URIC ACID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CANCER GROWTH; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG FORMULATION; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PATIENT ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; VITAL SIGN;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 77953755057     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Rosenberg B: Noble metal complexes in cancer chemotherapy. Adv Exp Med Biol 97: 129-150, 1977.
2. Livingston RB: Combination chemotherapy of bronchogenic carcinoma, I. Non-oat cell. Cancer Treat Rev 4: 153-165, 1977.
3. Al-sarraf M: Chemotherapeutic management of head and neck cancer. Cancer Metastasis Rev 6: 181-198, 1987.
4. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg L, Rosado K, Smart T, Yun Lin S, Penenberg D, Fair WR and Whitmore WF, Jr: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448-2458, 1989.
5. Oliver T and Mead G: Testicular cancer. Curr Opin Oncol 5: 559-567, 1993.
6. Taylor AE, Wiltshaw E, Gore ME, Fryatt I and Fischer C: Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 12: 2066-2070, 1994.
7. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909, 1995.
8. Humes HD: Insights into ototoxicity. Analogies to nephrotoxicity Ann NY Acad Sci 884: 15-18, 1999.
9. Arany I and Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol 23: 460-464, 2003.
10. Caraceni A, Marfini C, Spatti G, Thomas A and Onofrj M: Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta Neurol Scand 96: 260-261, 1997. (Pubitemid 27402496)
11. Boulikas T and Vougiouka M: Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs, (review) Oncol Rep 11: 559-595, 2004.
12. Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, Viliotou V and Stathopoulos JG: Pharmaco-kinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study. Oncology Rep 73: 589-595, 2005.
13. Boulikas T: Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 12: 3-12, 2004.
14. Devarajan P, Tarabishi R, Mishra J, Ma Q, Kourvetaris A, Vougiouka M and Boulikas T: Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res 24: 2193-2200, 2004.
15. Scaglioti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L and Tonato M, for the Italian Lung Cancer Project 2002: Phase III randomized trial comparing three platinum based doublets in advanced non-small cell lung cancer, J Clin Oncol 20: 4285-4291.
16. Taylor AE, Wiltshow E, Gore ME, Fryatt I and Fischer C: Long-term follow-up of the first randomized study of cisplatin versus Carboplatin for advanced epithelial ovarian cancer, J Clin Oncol 12: 2066-2070, 1994.
17. Stathopoulos GP, Rigatos SK, Christodoulou C, Malamos NA, Deliyiannis F, Stathopoulos JG and Skarlos DV: Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer Chemother Pharmacol 54: 259-264, 2004.
18. Stathopoulos GP, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K, Tsavdaridis D, Rigatos SK, Dimitroulis I, Bastani S, Loukides S, Vergos K, Marosis K, Grigoratou T, Kalatzi E, Charalambatou M, Paspalli A, Michalopoulou P, Stoka M and Gerogianni A: Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small cell lung cancer a randomized phase III trial. Ann Oncol 15: 1048-1055, 2004.
19. ICH Efficacy Guidelines EG (R1) Good clinical practice consolidated guideline, http://www.ich.org/cache/compo/475-272html.
20. Hanigan MH and Devarajan P: Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1: 47-61, 2003.
21. Santoso JT, Lucci JA III, Coleman RL, Schafer I and Hannigan EV: Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52: 13-18, 2003.
22. Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF and Woolley PV: Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol 5: 21-26, 1980.
23. Newman MS, Colbern CT, Working PK, Engbers C and Amantea MA: Comparative pharmacokinetics, of cisplatin encapsulated in long-circulating, pegylated liposomes (SPT-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43: 1-7, 1999.
24. Veal GJ, Griffin MJ, Price E, Parry A, Dick GS, Little MA, Yule SM, Morland B, Estlin EJ, Hale JP, Pearson AD, Welbank H and Boddy AV: A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome-encapsulated formulation of cisplatin. Br J Cancer 84: 1029-1035, 2001.